For research use only. Not for therapeutic Use.
Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC50s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively[1].
Tegeprotafib (Compound 124; 5 days) inhibits IFNγ (0.5 ng/mL) induced B16F10 cellular growth with a percent growth inhibition of 60-90% at 33 μM[1].
Tegeprotafib (Compound 124; 300 mg/kg; oral; BID for 21 days) shows antitumor activity in mice[1].
| Catalog Number | I041155 |
| CAS Number | 2407610-46-0 |
| Synonyms | 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| Molecular Formula | C13H11FN2O5S |
| Purity | ≥95% |
| InChI | InChI=1S/C13H11FN2O5S/c1-21-8-3-2-7-4-10(17)13(12(14)9(7)5-8)16-6-11(18)15-22(16,19)20/h2-5,17H,6H2,1H3,(H,15,18) |
| InChIKey | CPLSFGHDGOFDRP-UHFFFAOYSA-N |
| SMILES | COC1=CC2=C(C(=C(C=C2C=C1)O)N3CC(=O)NS3(=O)=O)F |
| Reference | [1]. Elliot FARNEY, et al. Protein tyrosine phosphatase inhibitors and methods of use thereof. Patent WO2019246513A1. |
